Mehrabi Joseph N, Friedman Or, Al-Niaimi Firas, Artzi Ofir
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Dr.Artzi and Associates - Treatment and Research Center.
J Cosmet Dermatol. 2020 Mar;19(3):612-621. doi: 10.1111/jocd.13285.
Picosecond (PS) lasers were approved by the US FDA in 2012 after being shown to remove tattoos with more success and fewer treatments compared with traditional methods. PS lasers were shown to be versatile, indicated for the treatment of lentigines, café-au-lait macules (CALMs), and acne scars and skin rejuvenation.
We report our experience treating our patients for different indications using a PS laser.
We performed a retrospective chart and photographic review of all patients seen between 2016 and 2018 that were treated in our centers with a PS laser for nontattoo indications. Clinical outcomes were evaluated using side-by-side comparisons of the clinical photographs by two blinded, independent physicians using a visual analog scale consisting of six levels of treatment response.
A total of 233 patients were studied. Most sought treatment for solar lentigo (27%) and skin rejuvenation (14%). Epidermal nevi exhibited the greatest improvement with treatment, while acne scarring demonstrated the least. Only 24% of patients experienced noteworthy, transient adverse effects.
Picosecond lasers were efficacious and safe for a variety of indications. They were effective in treating epidermal nevi and pigmented lesions, such as Lentigines and CALMs.
皮秒（PS）激光于2012年获得美国食品药品监督管理局（FDA）批准，因为与传统方法相比，它在去除纹身方面成功率更高且治疗次数更少。PS激光用途广泛，可用于治疗雀斑、咖啡斑（CALMs）、痤疮瘢痕以及皮肤年轻化。
我们报告使用PS激光治疗不同适应症患者的经验。
我们对2016年至2018年间在我们中心接受PS激光非纹身适应症治疗的所有患者进行了回顾性病历和照片审查。由两名不知情的独立医生使用由六级治疗反应组成的视觉模拟量表，通过并排比较临床照片来评估临床结果。
共研究了233例患者。大多数患者寻求治疗日光性雀斑（27%）和皮肤年轻化（14%）。表皮痣经治疗改善最大，而痤疮瘢痕改善最小。只有２４％的患者经历了值得注意的短暂不良反应。
皮秒激光对多种适应症有效且安全。它们在治疗表皮痣和色素沉着病变（如雀斑和咖啡斑）方面有效。
